Explore
Validate
Learn
ELISA
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 60311-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- HER2/ErbB2 antibody
- Antibody type
- Monoclonal
- Description
- HER2/ErbB2 antibody (Cat. #60311-1-Ig) is a mouse monoclonal antibody that shows reactivity with human and has been validated for the following applications: FC, IF, IHC,ELISA.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1B12A7
- Vial size
- 20ul, 150ul
Submitted references Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate.
Dual-receptor PET imaging of ovarian cancer using a (68)Ga-labeled heterodimer targeting folate receptor and HER2.
Synchronous neuroendocrine tumor and signet ring cell carcinoma in the stomach: a case report and review of literature.
Photoinduced Actin Aggregation Involves Cell Death: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.
The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing, and irreversibility of the G1/S transition.
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Targeted SERS Imaging and Intraoperative Real-Time Elimination of Microscopic Tumors for Improved Breast-Conserving Surgery.
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
InvivoPen: A novel plasma source for in vivo cancer treatment.
Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer.
HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.
He H, Chen X, Chen Y, Li Q, Yang F, Zhou L
International immunopharmacology 2026 Apr 1;174:116359
International immunopharmacology 2026 Apr 1;174:116359
Dual-receptor PET imaging of ovarian cancer using a (68)Ga-labeled heterodimer targeting folate receptor and HER2.
Shi X, Wu Z, Yuan Y, Wang Y, Yang S, Li R
American journal of nuclear medicine and molecular imaging 2025;15(4):130-139
American journal of nuclear medicine and molecular imaging 2025;15(4):130-139
Synchronous neuroendocrine tumor and signet ring cell carcinoma in the stomach: a case report and review of literature.
Han J, Wang Y, Mu H, Liu J
Frontiers in medicine 2025;12:1561231
Frontiers in medicine 2025;12:1561231
Photoinduced Actin Aggregation Involves Cell Death: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.
Sato K, Okada T, Okada R, Yasui H, Yamada M, Isobe Y, Nishinaga Y, Shimizu M, Koike C, Fukushima R, Takahashi K, Taki S, Kato A, Sato M, Ogura T
ACS nano 2025 Mar 4;19(8):8338-8356
ACS nano 2025 Mar 4;19(8):8338-8356
The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing, and irreversibility of the G1/S transition.
Nagasato-Ichikawa A, Murakami K, Aoki K, Okada M
The Journal of biological chemistry 2025 Dec;301(12):110865
The Journal of biological chemistry 2025 Dec;301(12):110865
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H, Wang W, Zhang Y, Chen Y, Shan C, Li J, Jia Y, Li C, Du C, Cai Y, Zhang Y, Zhang S, Wu F
International journal of cancer 2024 Jul 15;155(2):324-338
International journal of cancer 2024 Jul 15;155(2):324-338
Targeted SERS Imaging and Intraoperative Real-Time Elimination of Microscopic Tumors for Improved Breast-Conserving Surgery.
Wen Y, Liu R, Xie Y, Li M
Advanced materials (Deerfield Beach, Fla.) 2024 Aug;36(32):e2405253
Advanced materials (Deerfield Beach, Fla.) 2024 Aug;36(32):e2405253
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
Xing F, Gao H, Chen G, Sun L, Sun J, Qiao X, Xue J, Liu C
Molecular cancer 2023 Jan 10;22(1):6
Molecular cancer 2023 Jan 10;22(1):6
InvivoPen: A novel plasma source for in vivo cancer treatment.
Zhou X, Cai D, Xiao S, Ning M, Zhou R, Zhang S, Chen X, Ostrikov K, Dai X
Journal of Cancer 2020;11(8):2273-2282
Journal of Cancer 2020;11(8):2273-2282
Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer.
Wu Y, Meng Q, Yang Z, Shi L, Hu R, Zhang P, Wei J, Ren J, Leng B, Xu D, Jiang GQ
Oncology letters 2018 Sep;16(3):3726-3734
Oncology letters 2018 Sep;16(3):3726-3734
HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.
Wang J, Song L, Yang S, Zhang W, Lu P, Li S, Li H, Wang L
Molecular medicine reports 2017 Oct;16(4):4634-4642
Molecular medicine reports 2017 Oct;16(4):4634-4642
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The HER2/ErbB2 antibody from Proteintech is a mouse monoclonal antibody to a recombinant protein of human HER2/ErbB2. This antibody recognizes human antigen. The HER2/ErbB2 antibody has been validated for the following applications: ELISA, IHC analysis.
